FDA approved the original new drug application for IOMERVU on November 27, 2024, sponsored by BRACCO. FDA classed that submission a new molecular entity, which makes it the first approval of iomeprol in any product. FDA marks 9 of the application’s 13 products discontinued and the other 4 still marketed. FDA’s record shows no approved efficacy supplement on the application since.
- Application
- NDA216016
- Sponsor
- BRACCO
- Original approval
- Review
- standard review
- Submission class
- Type 1 - New Molecular Entity
- Active ingredient
- iomeprol
Browse every approval whose brand starts with I, or the complete response letters FDA has published — the applications it did not approve.
Products under this application
| Ingredient and strength | Form | Route | Marketing status |
|---|---|---|---|
| iomeprol 52.5GM IODINE/150ML (350MG IODINE/ML | SOLUTION | INTRA-ARTERIAL | Discontinued |
| iomeprol 17.5GM IODINE/50ML (350MG IODINE/ML) | SOLUTION | INTRA-ARTERIAL | Discontinued |
| iomeprol 60GM IODINE/150ML (400MG IODINE/ML) | SOLUTION | INTRA-ARTERIAL | Discontinued |
| iomeprol 45GM IODINE/150ML (300MG IODINE/ML) | SOLUTION | INTRA-ARTERIAL | Discontinued |
| iomeprol 20GM IODINE/50ML (400MG IODINE/ML) | SOLUTION | INTRA-ARTERIAL | Discontinued |
| iomeprol 15GM IODINE/50ML (300MG IODINE/ML) | SOLUTION | INTRA-ARTERIAL | Discontinued |
| iomeprol 70GM IODINE/200ML (350MG IODINE/ML) | SOLUTION | INTRA-ARTERIAL | Prescription |
| iomeprol 35GM IODINE/100ML (350MG IODINE/ML) | SOLUTION | INTRA-ARTERIAL | Prescription |
| iomeprol 80GM IODINE/200ML (400MG IODINE/ML) | SOLUTION | INTRA-ARTERIAL | Prescription |
| iomeprol 60GM IODINE/200ML (300MG IODINE/ML) | SOLUTION | INTRA-ARTERIAL | Discontinued |
| iomeprol 40GM IODINE/100ML (400MG IODINE/ML) | SOLUTION | INTRA-ARTERIAL | Prescription |
| iomeprol 30GM IODINE/100ML (300MG IODINE/ML) | SOLUTION | INTRA-ARTERIAL | Discontinued |
| iomeprol 25GM IODINE/100ML (250MG IODINE/ML) | SOLUTION | INTRA-ARTERIAL | Discontinued |
What “discontinued” means in FDA’s record
Drugs@FDA marks a product discontinued when it was never marketed, when it has been taken off the market, when it is made only for export, when it is made for military use, or when its approval was withdrawn for a reason other than safety or effectiveness. The record does not say which of those applies to a given product. The word on its own is not evidence that FDA found the drug unsafe.
Source: FDA, Drugs@FDA glossary of terms, under “Discontinued Drug Product”.
Approved efficacy supplements
An efficacy supplement is how a sponsor asks FDA to approve a change that needs clinical evidence — most often a new indication. FDA’s record gives each one a submission number, a date and a review priority. It does not say what any supplement approved, so neither does this page. The approval letter and label for each are on accessdata.fda.gov under the application number.
FDA’s record shows no approved efficacy supplement on this application.
Source: FDA’s Drugs@FDA application file, via openFDA (export 2026-09-03). Every field on this page comes from that record.
An approval date is the start of the question, not the end
What a drug is worth to the company that owns it depends on what else is in the pipeline, how much cash is behind it and who else is running the same trial. FuzeBio reads a biotech end to end on demand — pipeline in plain English, trial design and endpoints, competitors, the cash position, and a valuation with its assumptions on the page. Moderna’s report is open in full, no account.
Open the Moderna reportA complete sample report — nothing held back, no sign-up.